SCHEMBL2360137

SCHEMBL2360137

Nc1ncn(-c2ccc(Cl)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 5/20 0.46
F2 P00734 1/20 0.46
PKM P14618 2/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PI4KA P42356 1/20 0.40
PI4K2B Q8TCG2 1/20 0.40
PI4K2A Q9BTU6 1/20 0.40
PI4KB Q9UBF8 1/20 0.40
KDM4E B2RXH2 5/20 0.40
NPC1 O15118 4/20 0.40
MAPT P10636 4/20 0.40
RAB9A P51151 3/20 0.40
ATM Q13315 2/20 0.40
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
DHFR P00374 1/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20242932 0.80 NOTUM (0.41) NOTUMKDM4ENPC1MAPTRAB9A
SCHEMBL13662753 0.80 ALDH1A1 (0.43) NOTUML3MBTL1KDM4ENPC1MAPT
SCHEMBL13659759 0.79 NOTUM (0.50) NOTUMPKML3MBTL1NPSR1KDM4E
SCHEMBL2360711 0.79 MAPT (0.47) NOTUMPKML3MBTL1NPSR1KDM4E
SCHEMBL16202009 0.76 NOTUM (0.46) NOTUMF2L3MBTL1NPSR1KDM4E
SCHEMBL10360375 0.76 NOTUM (0.46) NOTUMF2PKML3MBTL1NPSR1
SCHEMBL18278742 0.76 RXRA (0.38) NPSR1ALDH1A1HPGDHSD17B10
SCHEMBL13822240 0.76 NPC1 (0.43) L3MBTL1NPSR1KDM4ENPC1MAPT
SCHEMBL18284894 0.76 DHFR (0.42) NOTUMADORA3ADORA2ADHFR
SCHEMBL31013386 0.74 NOTUM (0.43) NOTUMADORA3DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727549-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIV GEORGIA (US) 2026-04-09 US disclosed
WO-2024258900-A2 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
US-8288403-B2 Heterocyclic gamma secretase modulators HOFFMANN-LA ROCHE INC. (US) 2012-10-16 US disclosed
EP-2355817-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS F. Hoffmann-La Roche AG (CH) 2011-08-17 EP disclosed
WO-2010052199-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-14 WO disclosed
US-20100120874-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS HOFFMANN-LA ROCHE, INC. 2010-05-13 US disclosed
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof BROWN TRUMAN R 2006-04-27 US disclosed
US-5318982-A Inhibiting crosslinking of proteins THE ROCKEFELLER UNIVERSITY (US) 1994-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089316-A1 Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof ALDOA, FBP1, GYS2 NOTUM 2375/4885F2 804/4885PKM 952/4885
US-20100120874-A1 HETEROCYCLIC GAMMA SECRETASE MODULATORS BACE1, APH1A, APP NOTUM 2505/4885F2 355/4885PKM 4169/4885
US-20260097046-A1 PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS SUB1, PFN1, HCCS NOTUM 3845/4885F2 28/4885PKM 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.